Published in Int J Cancer on October 01, 2001
Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol (2008) 1.05
Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther (2013) 0.96
Prevalence and spectrum of microsatellite alterations in nonmuscle invasive bladder cancers. Am J Cancer Res (2011) 0.87
Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther (2008) 0.83
Genetic pathways and new progression markers for prostate cancer defined by microsatellite allelotyping. Urologe A (2004) 0.75
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Pyonephrosis: diagnosis and treatment. Br J Urol (1992) 1.97
EAU guidelines on prostate cancer. Eur Urol (2005) 1.88
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
Sacral colpopexy with concurrent Burch colposuspension in patients with vaginal vault prolapse. Urol Int (2006) 1.60
A star in a 15.2-year orbit around the supermassive black hole at the centre of the Milky Way. Nature (2002) 1.56
Decision support software to help primary care physicians triage skin cancer: a pilot study. Arch Dermatol (2000) 1.53
Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol (2003) 1.53
Pathology of human amebiasis. Hum Pathol (1970) 1.49
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Focal therapy in prostate cancer-report from a consensus panel. J Endourol (2010) 1.43
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. Aktuelle Urol (2006) 1.42
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer]. Aktuelle Urol (2009) 1.39
Aortic valve replacement: is the stentless xenograft an alternative to the homograft? Midterm results. Ann Thorac Surg (1999) 1.38
A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care (2002) 1.36
Purification and properties of rabbit liver phosphorylase phosphatase. J Biol Chem (1975) 1.34
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer (2011) 1.22
Giant calculus of the posterior urethra following recurrent penile urethral stricture. Urol Int (2002) 1.16
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer (2004) 1.15
Neuregulin signaling regulates neural precursor growth and the generation of oligodendrocytes in vitro. J Neurosci (2001) 1.13
[Cocaine-body-packing. Infrequent indication for laparotomy]. Chirurg (2003) 1.11
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol (2010) 1.08
Renal artery embolism: clinical features and therapeutic options. J Urol (1992) 1.08
A protein inhibitor of rabbit liver phosphorylase phosphatase. Biochem Biophys Res Commun (1975) 1.05
Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease. Cancer (1997) 1.05
[Gender-specific characteristics and survival of renal cell carcinoma]. Urologe A (2008) 1.05
Ureteroscopy without routine balloon dilation: an outcome assessment. J Urol (1992) 1.04
Radiommunological measurement of leptin in plasma of obese and diabetic human subjects. Endocrinology (1996) 1.03
Activation of phosphorylase phosphatase by a novel procedure: evidence for a regulatory mechanism involving the release of a catalytic subunit from enxyme-inhibitor complex(es) of higher molecular weight. Biochem Biophys Res Commun (1974) 1.01
Clinical experience with a new ultrasonic and LithoClast combination for percutaneous litholapaxy. BJU Int (2002) 0.99
Magnetic resonance imaging in the diagnosis of acute injured distal tibiofibular syndesmosis. Invest Radiol (1997) 0.99
Joint analysis of the influence of CYP11B1 and DGAT1 genetic variation on milk production, somatic cell score, conformation, reproduction, and productive lifespan in German Holstein cattle. J Anim Sci (2007) 0.99
Cardiac tamponade following pericarditis 18 days after catheter ablation of atrial fibrillation. Clin Res Cardiol (2010) 0.97
Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology (2011) 0.96
Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res (1990) 0.95
Internally concealed cocaine: analytical and diagnostic aspects. J Forensic Sci (1995) 0.95
Somatotopic mapping of the human primary somatosensory cortex by fully automated tactile stimulation using functional magnetic resonance imaging. Neurosci Lett (1999) 0.95
Factor XIII substitution in ulcerative colitis. Lancet (1995) 0.94
Local recurrence of an oncocytic adrenocortical carcinoma with ovary metastasis. J Urol (2001) 0.93
Quality-of-life issues in the treatment of testicular cancer. World J Urol (1999) 0.93
Purulent corporeal cavernositis secondary to papaverine-induced priapism. J Urol (1991) 0.92
The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol (2001) 0.92
Bitumen fumes: review of work on the potential risk to workers and the present knowledge on its origin. Sci Total Environ (2002) 0.91
[European Association of Urology guidelines on urinary and male genital tract infections]. Urologe A (2003) 0.89
[Immunochemical studies on the problem of the "pregnancy zone". VI. Occurrence, identification, and demonstration of the pregnancy-specific protein in the pregnancy zone]. Arch Gynakol (1972) 0.89
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol (2005) 0.89
Evidence for the coordinate control of activity of liver glycogen synthase and phosphorylase by a single protein phosphatase. J Biol Chem (1976) 0.89
Pseudo-pericardial tamponade after perforation of the right coronary artery. Heart (2004) 0.88
[Immunochemical studies of the problem of the "pregnancy zone". I. Antigravida immune serum]. Arch Gynakol (1969) 0.88
[Imaging diagnosis in suspected inflammatory rheumatoid axial skeleton diseases (sacroilitis)]. Z Rheumatol (1999) 0.87
[Immunochemical studies on the problem of the "pregnancy zone". VII. Radioimmunological studies on the affinity of pregnancy zone proteins to estrogens in vitro]. Arch Gynakol (1972) 0.87
Amoxapine overdose. Coma and seizures without cardiotoxic effects. JAMA (1982) 0.87
Anorexia nervosa trios: behavioral profiles of individuals with anorexia nervosa and their parents. Psychol Med (2008) 0.87
Polymorphism of the bovine CSN1S1 promoter: linkage mapping, intragenic haplotypes, and effects on milk production traits. J Dairy Sci (2003) 0.87
Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol (2005) 0.86
Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: results of a prospective randomized trial. J Urol (2003) 0.86
A cAMP-dependent phosphorylated motility protein in bovine epididymal sperm. J Biol Chem (1980) 0.86
[Isolated epididymal torsion in dissociation of testis-epididymis]. Urologe A (2002) 0.86
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp (2011) 0.85
[Guidelines for German urologists on diagnosis of benign prostate syndrome]. Urologe A (2003) 0.85
A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol (1997) 0.85
[Changes in blood rheology and microcirculation after preparatory combined thrombocytapheresis and plasmapheresis]. Beitr Infusionsther Transfusionsmed (1997) 0.85
[Inhibition of lymphocyte transformation in vitro by protein fractions from the serum of pregnant women and placental extracts]. Zentralbl Gynakol (1973) 0.85
[High-dose-rate brachytherapy of prostatic carcinoma with iridium 192]. Strahlenther Onkol (1992) 0.84
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol (2001) 0.84
Transcriptional and biochemical signatures of divergence in natural populations of two species of New Zealand alpine Pachycladon. Mol Ecol (2008) 0.84
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol (Praha) (2003) 0.84
Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost (1996) 0.84
[Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors]. Urologe A (2012) 0.84
[Guidelines of German urologists on therapy of benign prostate syndrome]. Urologe A (2003) 0.83
Initiation of sperm motility in the mammalian epididymis. Fed Proc (1978) 0.83
Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis (2002) 0.83
Genetic resistance to Heterakis gallinarum in two chicken layer lines following a single dose infection. Vet Parasitol (2008) 0.83
Management of contralateral adrenal metastasis from renal cell carcinoma: possibility of inferior vena cava tumour thrombus. Scand J Urol Nephrol (2000) 0.83
Familial paracentric inversion inv(2)(q31q36). Hum Genet (1985) 0.83
Identification of a new human Smad6 splice variant. Andrologia (2008) 0.83
Cryoablation of localized prostate cancer. Experience in 48 cases, PSA and biopsy results. Eur Urol (1998) 0.83